CA2437999C - Methodes de detection d'une proteine prion - Google Patents
Methodes de detection d'une proteine prion Download PDFInfo
- Publication number
- CA2437999C CA2437999C CA2437999A CA2437999A CA2437999C CA 2437999 C CA2437999 C CA 2437999C CA 2437999 A CA2437999 A CA 2437999A CA 2437999 A CA2437999 A CA 2437999A CA 2437999 C CA2437999 C CA 2437999C
- Authority
- CA
- Canada
- Prior art keywords
- target epitope
- polypeptide
- conformation
- epitope
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000003556 assay Methods 0.000 title abstract description 13
- 229920001184 polypeptide Polymers 0.000 claims abstract description 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 120
- 102000029797 Prion Human genes 0.000 claims abstract description 71
- 108091000054 Prion Proteins 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 69
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 54
- 201000010099 disease Diseases 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 102100025818 Major prion protein Human genes 0.000 claims description 56
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 claims description 47
- 239000000126 substance Substances 0.000 claims description 28
- 208000024827 Alzheimer disease Diseases 0.000 claims description 16
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 15
- 208000024777 Prion disease Diseases 0.000 claims description 15
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 14
- 210000002700 urine Anatomy 0.000 claims description 13
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000003599 detergent Substances 0.000 claims description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- 230000004845 protein aggregation Effects 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 230000003196 chaotropic effect Effects 0.000 claims description 4
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 4
- 150000002602 lanthanoids Chemical class 0.000 claims description 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 3
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims description 2
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 102000016252 Huntingtin Human genes 0.000 claims 2
- 108050004784 Huntingtin Proteins 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- 229940014800 succinic anhydride Drugs 0.000 claims 1
- 239000003223 protective agent Substances 0.000 abstract description 24
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 238000004220 aggregation Methods 0.000 abstract description 16
- 230000002776 aggregation Effects 0.000 abstract description 15
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000004925 denaturation Methods 0.000 abstract description 2
- 230000036425 denaturation Effects 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 description 56
- 101710138751 Major prion protein Proteins 0.000 description 52
- 238000001514 detection method Methods 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 28
- 239000000523 sample Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 241000699800 Cricetinae Species 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 15
- 239000004365 Protease Substances 0.000 description 15
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 14
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 14
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 14
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 13
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 12
- 208000008864 scrapie Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 9
- 238000001114 immunoprecipitation Methods 0.000 description 9
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 239000002981 blocking agent Substances 0.000 description 8
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 7
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 7
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 7
- 238000007385 chemical modification Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 7
- 229960004198 guanidine Drugs 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 4
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 229940125691 blood product Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 241000282994 Cervidae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000017580 chronic wasting disease Diseases 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000007387 gliosis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 101100272788 Arabidopsis thaliana BSL3 gene Proteins 0.000 description 1
- 101150068401 BSL1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019735 Meat-and-bone meal Nutrition 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100298534 Mus musculus Prnp gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100521383 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prp-5 gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000389 anti-prion effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- -1 compound peroxynitrite Chemical class 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 208000010544 human prion disease Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention a trait à un dosage de protection d'épitope destiné à servir dans le diagnostic, le pronostic et l'intervention thérapeutique dans le cas de maladies qui impliquent l'agrégation de polypeptides, telles que des infections par le prion. Les procédés selon l'invention permettent de bloquer en premier lieu l'épitope cible de polypeptide accessible au moyen d'un agent bloquant. Après dénaturation du polypeptide, on utilise un agent de détection pour détecter la protéine renfermant l'épitope cible qui était accessible lors du contact avec l'agent bloquant.
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2437999A CA2437999C (fr) | 2003-08-20 | 2003-08-21 | Methodes de detection d'une proteine prion |
| EP04761667.7A EP1668369B1 (fr) | 2003-08-20 | 2004-08-20 | Dosage de protection d'epitope et procede de detection de conformations proteiques |
| JP2006523496A JP4668191B2 (ja) | 2003-08-20 | 2004-08-20 | タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法 |
| US10/568,729 US20070003977A1 (en) | 2003-08-20 | 2004-08-20 | Epitope protection assay and method for detecting protein conformations |
| ES04761667.7T ES2566565T3 (es) | 2003-08-20 | 2004-08-20 | Ensayo de protección de epítopos y método para detectar conformaciones de proteínas |
| DK04761667.7T DK1668369T3 (en) | 2003-08-20 | 2004-08-20 | EPITOP PROTECTION ASSAY AND PROCEDURE FOR DETECTION OF PROTEIN COMPLIANCE |
| CA2536305A CA2536305C (fr) | 2003-08-20 | 2004-08-20 | Epitopes sod-1 et anticorps |
| AU2004266324A AU2004266324B8 (en) | 2003-08-20 | 2004-08-20 | Epitope protection assay and method for detecting protein conformations |
| PCT/CA2004/001503 WO2005019828A1 (fr) | 2003-08-20 | 2004-08-20 | Dosage de protection d'epitope et procede de detection de conformations proteiques |
| US11/367,609 US7439324B2 (en) | 2003-08-20 | 2006-03-03 | ALS-specific peptide composition |
| US12/236,731 US7763710B2 (en) | 2003-08-20 | 2008-09-24 | ALS-specific peptide composition |
| US12/792,394 US8075891B2 (en) | 2003-08-20 | 2010-06-02 | Antibodies that bind ALS specific epitopes and methods of making |
| JP2010153006A JP5357111B2 (ja) | 2003-08-20 | 2010-07-05 | Ｓｏｄ１ポリペプチド、免疫原、及びミスフォールディングしたｓｏｄ１に対する抗体 |
| US12/910,600 US9523697B2 (en) | 2003-08-20 | 2010-10-22 | Detection of pathogenic abeta using an epitope protection assay |
| US13/313,869 US8828389B2 (en) | 2003-08-20 | 2011-12-07 | Methods of diagnosing ALS |
| US14/448,584 US9625476B2 (en) | 2003-08-20 | 2014-07-31 | Methods of diagnosing ALS |
| US15/452,356 US20170192020A1 (en) | 2003-08-20 | 2017-03-07 | Methods of diagnosing als |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,437,675 | 2003-08-20 | ||
| CA002437675A CA2437675A1 (fr) | 2003-08-20 | 2003-08-20 | Methodes de detection de proteine prion |
| CA2437999A CA2437999C (fr) | 2003-08-20 | 2003-08-21 | Methodes de detection d'une proteine prion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2437999A1 CA2437999A1 (fr) | 2005-02-20 |
| CA2437999C true CA2437999C (fr) | 2013-10-08 |
Family
ID=34275919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2437999A Expired - Fee Related CA2437999C (fr) | 2003-08-20 | 2003-08-21 | Methodes de detection d'une proteine prion |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA2437999C (fr) |
| DK (1) | DK1668369T3 (fr) |
| ES (1) | ES2566565T3 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9637552B2 (en) | 2005-12-02 | 2017-05-02 | Promis Neurosciences Inc. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1668369B1 (fr) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Dosage de protection d'epitope et procede de detection de conformations proteiques |
| US7794692B2 (en) | 2005-12-02 | 2010-09-14 | Amorfix Life Sciences Ltd. | Methods and compositions for detecting amyotrophic lateral sclerosis |
| US7887803B2 (en) | 2005-12-02 | 2011-02-15 | Amorfix Life Sciences | Methods and compositions to treat misfolded-SOD1 mediated diseases |
-
2003
- 2003-08-21 CA CA2437999A patent/CA2437999C/fr not_active Expired - Fee Related
-
2004
- 2004-08-20 DK DK04761667.7T patent/DK1668369T3/en active
- 2004-08-20 ES ES04761667.7T patent/ES2566565T3/es not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9637552B2 (en) | 2005-12-02 | 2017-05-02 | Promis Neurosciences Inc. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2566565T3 (es) | 2016-04-13 |
| DK1668369T3 (en) | 2016-03-14 |
| CA2437999A1 (fr) | 2005-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9523697B2 (en) | Detection of pathogenic abeta using an epitope protection assay | |
| CA2693212A1 (fr) | Methode de detection d'oligomeres beta-amyloides dans des liquides organiques | |
| JP4422396B2 (ja) | ヒト起源の病原性プリオンを特異的に検出する抗体およびその体を用いて実施される検出方法 | |
| CA2437999C (fr) | Methodes de detection d'une proteine prion | |
| Kim et al. | Simple and specific detection of abnormal prion protein by a magnetic bead-based immunoassay coupled with laser-induced fluorescence spectrofluorometry | |
| Gielbert et al. | High‐resolution differentiation of transmissible spongiform encephalopathy strains by quantitative N‐terminal amino acid profiling (N‐TAAP) of PK‐digested abnormal prion protein | |
| CA2536305C (fr) | Epitopes sod-1 et anticorps | |
| CA2437675A1 (fr) | Methodes de detection de proteine prion | |
| ES2373762T3 (es) | Ensayo de priones. | |
| Silva | Applying the tools of chemistry (mass spectrometry and covalent modification by small molecule reagents) to the detection of prions and the study of their structure | |
| Moore et al. | Identification and removal of proteins that co‐purify with infectious prion protein improves the analysis of its secondary structure | |
| Kasai et al. | Novel assay with fluorescence-labelled PrP peptides for differentiating L-type atypical and classical BSEs, and scrapie | |
| Kretzschmar | Diagnosis of prion diseases | |
| Dabaghian et al. | An immunoassay for the pathological form of the prion protein based on denaturation and time resolved fluorometry | |
| Soto | Detection of prions in blood | |
| CN101084435A (zh) | 固定化的探针和检测构象改变的朊病毒蛋白的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210823 |